Pathobiology and molecular basis of MALT lymphoma

Extranodal Lymphomas: Pathology and Management

Volumn , Issue , 2008, Pages 67-76

  Bertoni, Francesco ^a   Gascoyne, Randy D ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955788437     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
2. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996; 87: 299-307.
3. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11; 18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601-9.
4. Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35-45.
5. Streubel B, Lamprecht A, Dierlamm J, et al. T(14; 18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2002; 101: 2335-9.
6. Streubel B, Vinatzer U, Lamprecht A, et al. T(3; 14)(p14.1; q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19: 652-8.
7. Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006; 30: 1546-53.
8. Zucca E, Bertoni F. Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa?. J Natl Cancer Inst 2006; 98: 1348-9.
9. Rollinson S, Levene AP, Mensah FK, et al. Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 2003; 102: 1007-11.
10. Cheng TY, Lin JT, Chen LT, et al. Association of Tcell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006; 24: 3483-9.
11. Mager D. Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med 2006; 4: 14.
12. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4: 644-53.
13. Jost PJ, Ruland J. Aberrant NF-{kappa}B signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood 2007; 109: 2700-7.
14. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 6370-8.
15. Bertoni F, Zucca E. Delving deeper into MALT lymphoma biology. J Clin Invest 2006; 116: 22-6.
16. Murga Penas EM, Hinz K, Roser K, et al. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia 2003; 17: 2225-9.
17. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003; 102: 1012-18.
18. Zucca E, Bertoni F, Cavalli F. Marginal zone B-cell lymphomas. In: Canellos GP, Lister TA, Young B, eds. The Lymphomas, 2nd edn. Philadelphia:Saunders Elsevier, 2006: 381-96.
19. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-30.
20. Hu S, Du MQ, Park SM, et al. Ubiquitination of Bcl10 by c-IAP2 and its dysregulation in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 2006; 116: 174-81.
21. Zhang Q, Siebert R, Yan M, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999; 22: 63-8.
22. Achuthan R, Bell SM, Leek JP, et al. Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma. Genes Chromosomes Cancer 2000; 29: 347-9.
23. Sanchez-Izquierdo D, Buchonnet G, Siebert R, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 2003; 101: 4539-46.
24. Dierlamm J, Rosenberg C, Stul M, et al. Characteristic pattern of chromosomal gains and losses in marginal zone B cell lymphoma detected by comparative genomic hybridization. Leukemia 1997; 11: 747-58.
25. Ho L, Davis RE, Conne B, et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005; 105: 2891-9.
26. Zhou H, Wertz I, O’Rourke K, et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004; 427: 167-71.
27. Lynch OT, Gadina M. Ubiquitination for activation:new directions in the NF-kappaB roadmap. Mol Interv 2004; 4: 144-6.
28. Che T, You Y, Wang D, et al. MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation. J Biol Chem 2004; 279: 15870-6.
29. Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol 2004; 4: 348-59.
30. Lucas PC, McAllister-Lucas LM, Nunez G. NFkappaB signaling in lymphocytes: a new cast of characters. J Cell Sci 2004; 117: 31-9.
31. Baens M, Fevery S, Sagaert X, et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 2006; 66: 5270-7.
32. Noels H, van Loo G, Hagens S, et al. A novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappa B activation by API2-MALT1 fusions. J Biol Chem 2007; 282: 10180-9.
33. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6: 287-97.
34. Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-94.
35. Alpen B, Neubauer A, Dierlamm J, et al. Transloca - tion t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000; 95: 4014-15.
36. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11; 18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40.
37. Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106: 1037-41.
38. Ye H, Gong L, Liu H, et al. Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. Gut 2006; 55: 137-8.
39. Kuo SH, Chen LT, Yeh KH, et al. Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. J Clin Oncol 2004; 22: 3491-7.
40. Streubel B, Ye H, Du MQ, et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004; 66: 476-80.
41. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-83.
42. Banham AH, Beasley N, Campo E, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 2001; 61: 8820-9.
43. Hu H, Wang B, Borde M, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol 2006; 7: 819-26.
44. Sagaert X, de Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 2490-7.
45. Wlodarska I, Veyt E, De Paepe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large Bcell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19: 1299-305.
46. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933-5.
47. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065-72.
48. Gaidano G, Volpe G, Pastore C, et al. Detection of BCL-6 rearrangements and p53 mutations in Maltlymphomas. Am J Hematol 1997; 56: 206-13.
49. Gaidano G, Capello D, Gloghini A, et al. Frequent mutation of bcl-6 proto-oncogene in high grade, but not low grade, MALT lymphomas of the gastrointestinal tract. Haematologica 1999; 84: 582-8.
50. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000; 95: 651-9.
51. Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 2007; 109: 3500-4.
52. Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature Bcell entities: a description of 103 cases. Leukemia 2005; 19: 1818-23.
53. Torlakovic EE, Aamot HV, Heim S. A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma. J Pathol 2006; 209: 258-64.
54. Starostik P, Greiner A, Schultz A, et al. Genetic aberrations common in gastric high-grade large B-cell lymphoma. Blood 2000; 95: 1180-7.
55. Zhou Y, Ye H, Martin-Subero JI, et al. Distinct comparative genomic hybridisation profiles in gastric mucosaassociated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). Br J Haematol 2006; 133: 35-42.
56. Krugmann J, Tzankov A, Dirnhofer S, et al. Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas. J Clin Pathol 2004; 57: 360-4.
57. Krugmann J, Tzankov A, Dirnhofer S, et al. Complete or partial trisomy 3 in gastro-intestinal MALT lymphomas co-occurs with aberrations at 18q21 and correlates with advanced disease stage: a study on 25 cases. World J Gastroenterol 2005; 11: 7384-5.
58. Taji S, Nomura K, Matsumoto Y, et al. Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy. World J Gastroenterol 2005; 11: 89-93.
59. Tanimoto K, Sekiguchi N, Yokota Y, et al. Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. BMC Cancer 2006; 6: 249.
60. Chan JK, Ng CS, Isaacson PG. Relationship between high-grade lymphoma and low-grade B-cell mucosa- associated lymphoid tissue lymphoma (MALToma) of the stomach. Am J Pathol 1990; 136: 1153-64.
61. Barth TF, Barth CA, Kestler HA, et al. Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma. J Pathol 2007; 211: 305-13.
62. Kuo SH, Chen LT, Wu MS, et al. Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression. J Pathol 2007; 211: 296-304.
63. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002; 99: 3-9.
64. Qin Y, Greiner A, Trunk MJ, et al. Somatic hypermutation in low-grade mucosa-associated lymphoid tissue- type B-cell lymphoma. Blood 1995; 86: 3528-34.
65. Du M, Diss TC, Xu C, et al. Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia 1996; 10: 1190-7.
66. Dono M, Ferrarini M. Immunoglobulin gene mutation patterns and heterogeneity of marginal zone lymphoma. Methods Mol Med 2005; 115: 173-96.
67. Bertoni F, Cazzaniga G, Bosshard G, et al. Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. Br J Haematol 1997; 97: 830-6.
68. Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1997; 89: 3335-44.
69. Greiner A, Marx A, Heesemann J, et al. Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis. Lab Invest 1994; 70: 572-8.
70. Zucca E, Bertoni F, Roggero E, et al. Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach. Leukemia 1998; 12: 247-9.
71. Bertoni F, Cotter FE, Zucca E. Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. Leuk Lymphoma 1999; 35: 57-68.
72. Lenze D, Berg E, Volkmer-Engert R, et al. Influence of antigen on the development of MALT lymphoma. Blood 2006; 107: 1141-8.
73. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2: 323-35.
74. Ohmae T, Hirata Y, Maeda S, et al. Helicobacter pylori activates NF-kappaB via the alternative pathway in B lymphocytes. J Immunol 2005; 175: 7162-9.
75. Paternoster SF, Brockman SR, McClure RF, et al. A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol 2002; 160: 1967-72.
76. Gascoyne RD. Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas. Hematology (Am Soc Hematol Educ Program) 2005: 299-306.
77. Du MQ, Atherton JC. Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. Gut 2006; 55: 886-93.
78. Campo E, Chott A, Kinney MC, et al. Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology 2006; 48: 481-504.
79. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variableregion mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75.
80. Nakagawa M, Hosokawa Y, Yonezumi M, et al. MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood 2005; 106: 4210-16.
81. Sagaert X, De Wolf-Peeters C, Noels H, et al. The pathogenesis of MALT lymphomas: where do we stand?. Leukemia 2007; 21: 389-96.